VR Logo

Unicycive Therapeutics Inc. (UNCY) download report


Healthcare | Biotechnology & Pharma Research

Unicycive Therapeutics Inc. (UNCY) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States.

IPO Date: 12-Jul-2021

Founder, Chairman, CEO & Pres: Dr. Shalabh K. Gupta M.D., MPA

Chief Financial Officer: Mr. John W. Townsend CPA

Listing: NASDAQ: UNCY

Country: United States

Headquarters: Los Altos, CA

Website: https://www.unicycive.com

Key Facts

Market cap: $12.32 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-12.59 Mln

Cash: $13.62 Mln

Total Debt: $0.30 Mln

Insider's Holding: 41.09%

Liquidity: Low

52 Week range: $0.64 - 8.73

Shares outstanding: 15,028,500

Stock Performance

Time Period Unicycive Therapeutics (UNCY) S&P BSE Sensex S&P Small-Cap 600
YTD-60.19-7.86-19.79
1 month-2.38-3.75-9.59
3 months-38.35-10.80-13.28
1 Year--1.50-17.92
3 Years--10.755.46
5 Years--11.435.57
10 Years--11.849.48
As on 06-Jul-2022